Terns Pharmaceuticals, Inc. Stock Price, News & Analysis

Terns Pharmaceuticals (NASDAQ: TERN) announced that preclinical data for its TERN-701, a next-generation allosteric BCR-ABL inhibitor for chronic myeloid leukemia (CML), will be presented at the 30th European Hematology Association Congress in June 2025. The data demonstrates superior potency compared to asciminib across multiple BCR-ABL variants, including difficult-to-treat resistance mutations.

Early Phase 1 CARDINAL study results showed promising molecular responses in heavily pre-treated CML patients, with improved responses in those who had poor response to asciminib. The company expects to release additional safety and efficacy data, including 6-month major molecular response (MMR) rates, in Q4 2025.

Terns Pharmaceuticals (NASDAQ: TERN) reported Q1 2025 financial results and provided updates on its clinical pipeline. The company highlighted progress in two key programs: TERN-701 for chronic myeloid leukemia (CML) and TERN-601 for obesity. The Phase 1 CARDINAL trial for TERN-701 has advanced to dose expansion, with additional data expected in Q4 2025. The Phase 2 FALCON trial for TERN-601 is enrolling well, with top-line 12-week weight loss data anticipated in Q4 2025.

Financially, Terns reported cash and equivalents of $334.3 million as of March 31, 2025, with a runway extending into 2028. The company posted a net loss of $23.9 million for Q1 2025, compared to $22.4 million in Q1 2024. R&D expenses were $18.7 million, while G&A expenses increased to $8.7 million from $6.9 million year-over-year.

Terns Pharmaceuticals (NASDAQ: TERN), a clinical-stage biopharmaceutical company focused on developing small-molecule treatments for oncology and obesity, has announced equity inducement grants to two new employees. The grants, approved under the 2022 Employment Inducement Award Plan and in compliance with Nasdaq Listing Rule 5635(c)(4), include:

- Options to purchase 325,000 shares of Terns common stock - Exercise price of $3.56 per share (closing price on May 1, 2025) - 10-year term options - Four-year vesting period, contingent on continued employment

Terns Pharmaceuticals (Nasdaq: TERN), a clinical-stage biopharmaceutical company focused on developing small-molecule treatments for serious diseases including oncology and obesity, has announced its upcoming participation in The Citizens Life Sciences Conference.

The company's senior management team will engage in a fireside chat scheduled for Wednesday, May 7, 2025, at 2:30 p.m. ET. Investors and interested parties can access the live webcast through Terns Pharmaceuticals' investor relations website at http://ir.ternspharma.com.

The presentation will be archived on the company's website for a minimum of 30 days after the event, allowing stakeholders who cannot attend the live session to review the discussion at their convenience.

Terns Pharmaceuticals (TERN), a clinical-stage biopharmaceutical company focused on developing small-molecule treatments for oncology and obesity, has announced equity inducement grants to two new employees. The grants, approved under the 2022 Employment Inducement Award Plan and Nasdaq Listing Rule 5635(c)(4), consist of options to purchase 611,000 shares of Terns common stock.

The stock options come with a 10-year term and an exercise price of $2.56 per share, matching Terns' closing stock price on April 1, 2025. These options will vest over a four-year period, contingent on continued employment through the vesting dates.

Terns Pharmaceuticals (TERN) has reported its Q4 and full year 2024 financial results, highlighting significant clinical progress in its pipeline. The company ended 2024 with $358.2 million in cash and equivalents, providing runway into 2028.

Key developments include:

• Phase 1 CARDINAL trial of TERN-701 for chronic myeloid leukemia (CML) completed dose escalation, with dose expansion expected in Q2 2025
• First patient enrolled in Phase 2 FALCON trial of TERN-601 for obesity, with 12-week data expected in Q4 2025
• TERN-601 demonstrated weight loss up to 5.5% over 28 days in Phase 1 trials

Financial results show R&D expenses of $70.1 million for 2024 (up from $63.5 million in 2023), G&A expenses of $31.8 million (down from $39.1 million in 2023), and a net loss of $88.9 million (improved from $90.2 million in 2023).

Terns Pharmaceuticals (Nasdaq: TERN) has granted an equity inducement award to its new Chief Financial Officer, Andrew Gengos, as announced on February 26, 2025. The award, approved under the 2022 Employment Inducement Award Plan and in accordance with Nasdaq Listing Rule 5635(c)(4), consists of an option to purchase 750,000 shares of Terns common stock.

The stock option features a 10-year term with an exercise price of $3.73 per share, matching Terns' closing stock price on February 24, 2025. The option will vest over a four-year period, contingent upon Mr. Gengos maintaining his employment with the company.

Terns Pharmaceuticals (TERN) has provided program updates across its development pipeline and announced participation at the TD Cowen 45th Annual Healthcare Conference. The company reported strong progress with its TERN-701 CARDINAL study for chronic myeloid leukemia (CML), with dose expansion expected to begin in Q2 2025 and additional data in Q4 2025. New data shows TERN-701 has an improved drug-drug interaction profile compared to asciminib.

For its obesity program, Terns introduced the Phase 2 FALCON study design for TERN-601, an oral GLP-1 receptor agonist, scheduled to begin in early Q2 2025 with 12-week data expected in 2H 2025. The company aims to achieve competitive weight loss with best-in-class tolerability without complicated dose titrations.

Terns continues evaluating opportunities for TERN-501 in metabolic diseases and is advancing its TERN-800 series of GIPR modulators for obesity. With $372.8 million in cash as of September 30, 2024, the company expects runway into 2028.

Terns Pharmaceuticals (Nasdaq: TERN) has appointed Andrew Gengos as Chief Financial Officer, effective immediately. Gengos brings 25 years of leadership experience in biotech and life sciences to the clinical-stage biopharmaceutical company.

Gengos most recently served as CFO of Athira Pharma and previously as Chief Business Officer at Cyteir Therapeutics, where he led the company's IPO finance team. His experience includes CEO roles at ImmunoCellular Therapeutics and Neuraltus Pharmaceuticals, and eight years as VP of Strategy and Corporate Development at Amgen.

The appointment comes as Terns, which focuses on developing small-molecule product candidates for oncology and obesity, anticipates clinical readouts later this year. Gengos holds an MBA from UCLA Anderson School of Management and a BS in Chemical Engineering from MIT.